Real-world evidence highlights the urgent need to act on the

AstraZeneca, a leader in cardiorenal diseases, presented new real-world evidence (RWE) data at the European Renal Association (ERA) 2023 Congress in Milan, Italy, demonstrating the staggeringly low rate of diagnosis in chronic kidney disease (CKD). These data show that an urgent need exists for improved screening ...

Related Keywords

United Kingdom , Cambridge , Cambridgeshire , Milan , Lombardia , Italy , Canada , Spain , United States , Brazil , Australia , , Company On Twitter , European Renal Association , National Kidney Foundation , Centers For Disease , Astrazeneca , Nasdaq , Undiagnosed Stage , Accelerating Change Together , Executive Vice President , Biopharmaceuticals Business Unit , Kidney Disease Improving Global Outcomes , Rare Diseases , Prevalence Of Undiagnosed Stage , Kidney Disease In Australia , Canada And , Clinical Outcomes Associated , Recorded Diagnosis , Kidney Disease , Global Burden , Disease Study , Nephrol Dial , Kidney Foundation , Chronic Kidney Disease , Disease Control , Curr Cardiol ,